Biocon gets 10 observations from USFDA for Benguluru plant: Report

04 Aug 2017 Evaluate

Regulatory woes continue for Biocon, as United States Foods and Drug Administration (USFDA) has reportedly issued a form 483 with 10 observations to its Bangalore plant. The US drug regulator found lapses of current good manufacturing practices (cGMP) at the company’s small molecule injectable plant in Bengaluru.

The USFDA issued a Form 483 - a form listing violations - after an inspection between May 25 and June 3. The FDA issues a Form 483 if its investigators spot any conditions that in their judgement may constitute violations of the US Food Drug and Cosmetic (FD&C) Act and related laws.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

365.25 -1.15 (-0.31%)
27-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1639.30
Dr. Reddys Lab 1240.00
Cipla 1312.85
Zydus Lifesciences 893.45
Lupin 2147.60
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×